cisplatin,gemcitabine,nivolumab
bms
['gu ', 'nivolumab', 'cisplatin', 'hcrn,gu,16-257', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'nivo', 'gemcitabine', 'bladder']
hcrn gu 16-257 2-year bladder-intact survival is achieved in the majority of patients with a ccr. higher tmb better outcomes
#gu23 #medtwitter 
On the road!
Pursuing to improve global health through sharing knowledge, cancer prevention, and care.  
Medical oncologist @AnkaraUni